Nizwaside: a new anticancer pregnane glycoside from the sap of Desmidorchis flava
| Autor: | René Csuk, Ali Elyassi, Ahmed Al-Rawahi, Mohammed Al-Broumi, Ahmed Al-Harrasi, Hidayat Hussain, Ghulam Abbas, Najeeb Ur Rehman, Husain Yar Khan, Ivan R. Green, Muhammad Adil Raees, Talat Mahmood |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Antioxidant
DPPH Cell Survival medicine.medical_treatment Pharmacology chemistry.chemical_compound Cell Line Tumor Drug Discovery medicine Humans Doxorubicin Glycosides skin and connective tissue diseases IC50 Natural product Dose-Response Relationship Drug Cell growth Plant Extracts Organic Chemistry Pregnanes Acetylcholinesterase Antineoplastic Agents Phytogenic Apocynaceae chemistry Molecular Medicine Female Two-dimensional nuclear magnetic resonance spectroscopy medicine.drug |
| Zdroj: | Archives of pharmacal research. 38(12) |
| ISSN: | 1976-3786 |
| Popis: | The sap from the succulent Desmidorchis flava (N.E.Br) Meve and Liede yielded a new pregnane glycoside, named nizwaside whose structure was established using 1D and 2D NMR techniques as well as mass spectrometry (ESIMS). Nizwaside was tested for anticancer, DPPH antioxidant, urease enzyme inhibition, α-glucosidase enzyme inhibition and acetylcholinesterase inhibition activities. Interestingly, nizwaside showed significant anti-proliferative effects on MDA MB231 breast cancer cells with an IC(50) of 23.5 µg/ml. Moreover, nizwaside was more effective than Doxorubicin, a well-known clinical anticancer drug, in suppressing MDA MB231 cell proliferation even at concentrations lower than that of Doxorubicin (75 µg/ml nizwaside vs. 100 µg/ml Doxorubicin). On the other hand, nizwaside showed relatively weak antioxidant activity with 15 % inhibition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink